Showing results (21-30 of 163) with videos related to

Sort By:
Pageof 17
Haematologica|February 12, 2026
Intrinsic cellular resistance to BCR::ABL1 inhibitorsNataly Cruz-Rodriguez, Yulieth Torres-Llanos, Michael W Deininger
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2016
New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic LandscapeAmi B Patel, Nadeem A Vellore, Michael W Deininger
Expert Review of Hematology|May 18, 2017
Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?Ami B Patel, Brandon W Wilds, Michael W Deininger
Clinical Case Reports|June 12, 2019
Lysozyme nephropathy in chronic myelomonocytic leukemiaAmi B Patel, Rodney R Miles, Michael W Deininger
The EMBO Journal|December 1, 1995
Chlamyrhodopsin represents a new type of sensory photoreceptorW Deininger, P Kröger, U Hegemann, et al.
Cancer Medicine|August 9, 2023
Population modeling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemiaMay Garrett, Beverly Knight, Jorge E Cortes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2019
ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation?Dongqing Yan, Anthony D Pomicter, Thomas O'Hare, et al.
BMC Medicine|August 27, 2011
Advances in the treatment of chronic myeloid leukemiaAnna M Eiring, Jamshid S Khorashad, Kimberly Morley, et al.
Current Hematologic Malignancy Reports|August 31, 2017
Minimal Residual Disease Eradication in CML: Does It Really Matter?Srinivas K Tantravahi, Raga S Guthula, Thomas O'Hare, et al.
Clinical Lymphoma & Myeloma|March 4, 2009
New strategies for the first-line treatment of chronic myeloid leukemia: can resistance be avoided?Jennifer L Snead, Thomas O'Hare, Christopher A Eide, et al.
Pageof 17